Vanderbilt Talk

Document Sample
Vanderbilt Talk Powered By Docstoc
					  NCI/NIST Perspective on IGI
Research and Related Standards

   Laurence P. Clarke PhD, FAAPM;
                 FISMRM

     NCI, DCTD, Cancer Imaging Program
               Detail (NIBIB)
           Guest Scientist ( NIST)
      “NCI GT” and NA-MIC Workshop
              Oct 19th st 2006
  NCI Initiatives: Imaging Standards
• NTROI: Systems approach to validating optical imaging
  platforms and related standards
• LIDC-RIDER: Database resource for standardized
  benchmarking of software tools.
• NCI caBIG: Imaging workspace and workstation: focus
  open source validation tools.
• Trans Agency: Public Private Partnerships
   – Oncology Biomarker Qualification Initiative (OBQI)
   – Biomarker Consortium: Pharma Oct 5th 2006
   – NIST Trans Agency Workshop: Imaging standards.
• NEW PAR: RO1:
   – Academic-Industry Partnerships
  NTROI Objectives: U54: 2003-08
             Build an international research network to
             develop a systems approach for molecular
             imaging for drug discovery, drug response
             and IG delivery
• Bridge disciplines: Oversight by a steering
  committee: Funded activity.
  – Connect instrumentation development teams to
    biologists, chemists, and clinical teams
  – Sharing of optical and molecular imaging probes and
    cross validation studies
  – Sharing common IT and open source tools
  – Engage scientists with different federal agencies and
    industry: FDA, NIST, NIH and over 30 cooperate
    partners, to develop broad consensus on validation
    methods that may lead to imaging standards.
      NTROI: Techniques and Organ Systems

•   Team 1: UC Irvine--Breast Cancer
       Diffuse optical imaging and spectroscopy


• Team 2: Boston University--Esophageal Cancer
    Elastic scattering spectroscopy and optical
       pharmacokinetics" (fast UV through IR
      analytical in vivo spectrophotometry)

                                                                                      Optical “biopsy”
• Team 3: Univ. of Pennsylvania--Animal models of
   GI cancer                                                  EGFR
    In vivo bioluminescence imaging and optical
       measures of metabolic activity


• Team 4: Stanford University--GI Cancers
    Fiber-based confocal microscopy for in vivo             QuickTime™ and a
                                                         Graphics decompressor




    measures of histopathology
                                                    are needed to see this picture.
 Open Source Acquisition and Analysis Platform
          Cross Validation Studies
           Clinical Decision Tools
     Technologies
                                                               Clinical
                                                                Trials


                                                    Multi-vendor compatible
                                                    IT for efficient clinical
                                                    trials, and rapid
                                                    translation to products
                                                    from multiple vendors
                                Drive rapid convergence of scientific consensus
                                and validation
                                thru shared databases and software

                    Improve Optical Tomography & Enhance Clinical Utility of Optical Data
Deliverables                             Objectives
Reference Image Database for
  Drug Response (RIDER)
  Resource: Benchmarking Performance of
      Change Analysis Software:
Consensus on methods and measure
     sources of uncertainty .
                                                         Standardized
 Imagery + mark up “truth”                           Performance Analysis
                                                        (Computer ROC)
                             Corpus
                             (Large)
                                                                No change
             Development          Sequestered for
               Set                    Testing       Shrinkage               Growth




    Change Analysis Tools
                                                NCI NIBIB: 2 Fellows (FDA)
Image registration; pixel                       NIST Scientists: 2 FTE’s
                                                RIDER Academic Scientists
intensity/density change,
                                                Industry Scientists
volume or shape.. …
One potential method
      to engage
 stakeholders for IGI
      standards
      NIST Workshop Report
• The NIST meeting was a stakeholders
  meeting attended by 260 scientists:
  – Imaging and Pharma Companies,
  – CRO’s and Trade Organizations
    • (NEMA, PhRMA Consortium),
  – RSNA, ACR, AAPM, SNM, ISMRM
  – Federal Government
    • (NIH: NCI, NIBIB, NIA, NIAMS, NIGM, NCRR)
    • FDA (CDRH, CDER)
    • NIST (CSTL, EEEL, PL, MSEL, MEL ).
      NIST Workshop Report
• There was a very strong agreement
  across all stakeholders that:
  – uncertainty in data collection and analysis
    across single and different imaging platforms
    was an important problem for quantitative
    measurements as applied to drug trials
  – i.e.., in addition to the biological uncertainty,
    which was not a focus of this workshop.
        NIST Workshop Report
• There was a strong interest by all stakeholders
  to address these measurement problems and
  proposed several short, mid- and long-term
  recommendations to implement standards:
  – Several academic societies are willing to both
    support and collaborate with Gov. agencies ,
    leveraging the volunteer time of their members.
  – NEMA expressed interest in representing the
    imaging industry in any interagency or NIST effort,
    and partner with PHRMA
  – RSNA expressed an interest in helping to facilitate
    follow up stakeholders meetings, IHE was posed as
    an example, that was industry lead.
         Examples of Areas Mentioned
• Define the physical performance of different imaging
  platforms required to measure change analysis.
• Design phantoms that may better characterize the time
  related physical performance of imaging systems, and the
  performance for specific functional and molecular based
  measurements.
• Develop and share open source tools to analyze phantom or
  simulated data.
• Develop and share open source tools for validation and
  image mark up of clinical data, including statistical methods.
• Develop public resources to help optimize and validate
  imaging methods prior to their implementation in drug trials.
• Develop scalable resources to archive de-identified image
  and meta data, in collaboration with industry.
NCI PAR: Academic-Industry Partnerships
• R01: Goal: Accelerate translational research, encourage delivery
  of technologies and methods for multi site clinical trials. April 1 st
  2007.

•   Partnerships Required or encouraged.
    – Industry Device and/ or Pharma required.
    – Collaboration with NIH intramural, FDA, NIST scientists,
      through the use of visiting scientists
    – Multi PI’s and linked R01’s permitted
    – Collaboration with other cooperative agreements

• Research emphasis:
   – Imaging Platforms: Human and Pre Clinical
   – Validation of multi-modality imaging platforms
   – Open source architecture and software tools
   – Development of public resource for Q/C, validation of imaging
       methods- software tools
              URL’s for reference
• NCI CIP Program: : http://imaging.cancer.gov/

• NCI FDA IOTF: http://iotftraining.nci.nih.gov/

• OBQI:     http://ww.cancer.gov/newscenter/pressreleases/OBQI

• FDA new pathways report: Drug Response:
  http://www.fda.gov/oc/initiatives/criticalpath/

• RIDER Database resource for software evaluation:
• http://imaging.nci.nih.gov/i3/

• NIST Workshop: http://usms.nist.gov/workshops/bioimaging.htm

• NIH Road Map: http://nihroadmap.nih.gov/bioinformatics/grants.asp

				
DOCUMENT INFO
Shared By:
Categories:
Tags:
Stats:
views:24
posted:8/23/2011
language:English
pages:14